Baxter International Faces Class Action Over Alleged Securities Violations and Product Defects
On October 24, 2025, Levi & Korsinsky, LLP announced that a class action lawsuit has been filed against Baxter International, Inc. (NYSE: BAX), illuminating serious allegations regarding the company's securities practices and product safety. This legal action comes at a time when investor confidence in Baxter is at stake, particularly in light of claims that its products could have endangered patients.
The lawsuit focuses on securities fraud that allegedly occurred between February 23, 2022, and July 30, 2025. It seeks to recover losses for those affected during this period, raising questions about the integrity of the company's communications and the safety of its products. According to the compliant, Baxter reportedly misled investors by failing to disclose significant issues with its recently launched product, the Novum LVP, which had systemic defects that led to a range of malfunctions. These malfunctions included underinfusion, overinfusion, and complete failure to deliver fluids, posing serious health risks to patients.
Furthermore, it is claimed that Baxter was previously notified of multiple malfunctions, alongside associated injuries and even fatalities. Instead of implementing effective remedies, the company reportedly relied on inadequate alerts to address these dangers, which persisted, leading to profound concerns about patient safety. This has not bode well for Baxter, as investors have been made aware that ongoing problems could result in customers being advised to take existing Novum LVPs out of service, and that new sales of these units might be completely halted. Therefore, the lawsuit asserts that statements made by Baxter regarding the safety, efficiency, and market potential of the Novum LVP were fundamentally misleading.
For investors who feel they have suffered damages in Baxter during the specified timeframe, there is still an opportunity to take action. They have until December 15, 2025, to request to be appointed as lead plaintiff in the ongoing litigation. Importantly, participating in this class action does not require individuals to be lead plaintiffs to qualify for potential compensation. Moreover, there are no upfront costs for involved individuals—class members may be eligible for compensation without bearing any out-of-pocket fees.
With over two decades of experience handling securities litigation, Levi & Korsinsky has a successful history of securing substantial financial recoveries for shareholders affected by corporate misconduct. Their competent team has established a reputation for being among the leading firms in this domain, consistently ranked in ISS Securities Class Action Services' Top 50 list. For those looking to learn more about their rights or to engage with this case, legal representatives from Levi & Korsinsky are available; interested parties can contact attorney Joseph E. Levi or fill out a submission form through their official website to begin the process.
In summary, the accusations leveled against Baxter International highlight not only potential violations of securities law but also raise critical questions regarding their commitment to product safety and customers. Investors who have faced losses during the tumultuous timeframe stipulated in the lawsuit are encouraged to seek legal counsel and protect their interests.
The lawsuit focuses on securities fraud that allegedly occurred between February 23, 2022, and July 30, 2025. It seeks to recover losses for those affected during this period, raising questions about the integrity of the company's communications and the safety of its products. According to the compliant, Baxter reportedly misled investors by failing to disclose significant issues with its recently launched product, the Novum LVP, which had systemic defects that led to a range of malfunctions. These malfunctions included underinfusion, overinfusion, and complete failure to deliver fluids, posing serious health risks to patients.
Furthermore, it is claimed that Baxter was previously notified of multiple malfunctions, alongside associated injuries and even fatalities. Instead of implementing effective remedies, the company reportedly relied on inadequate alerts to address these dangers, which persisted, leading to profound concerns about patient safety. This has not bode well for Baxter, as investors have been made aware that ongoing problems could result in customers being advised to take existing Novum LVPs out of service, and that new sales of these units might be completely halted. Therefore, the lawsuit asserts that statements made by Baxter regarding the safety, efficiency, and market potential of the Novum LVP were fundamentally misleading.
For investors who feel they have suffered damages in Baxter during the specified timeframe, there is still an opportunity to take action. They have until December 15, 2025, to request to be appointed as lead plaintiff in the ongoing litigation. Importantly, participating in this class action does not require individuals to be lead plaintiffs to qualify for potential compensation. Moreover, there are no upfront costs for involved individuals—class members may be eligible for compensation without bearing any out-of-pocket fees.
With over two decades of experience handling securities litigation, Levi & Korsinsky has a successful history of securing substantial financial recoveries for shareholders affected by corporate misconduct. Their competent team has established a reputation for being among the leading firms in this domain, consistently ranked in ISS Securities Class Action Services' Top 50 list. For those looking to learn more about their rights or to engage with this case, legal representatives from Levi & Korsinsky are available; interested parties can contact attorney Joseph E. Levi or fill out a submission form through their official website to begin the process.
In summary, the accusations leveled against Baxter International highlight not only potential violations of securities law but also raise critical questions regarding their commitment to product safety and customers. Investors who have faced losses during the tumultuous timeframe stipulated in the lawsuit are encouraged to seek legal counsel and protect their interests.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.